Mechanism of bulleyaconitine A in inhibiting bone destruction of rheumatoid arthritis via Src/PI3K/Akt signaling pathway
Based on the sarcoma receptor coactivator(Src)/phosphatidylinositol 3-kinase(PI3K)/protein kinase B(Akt)signa-ling pathway,the mechanism of action of bulleyaconitine A in the treatment of bone destruction of experimental rheumatoid arthritis(RA)was explored.Firstly,key targets of RA bone destruction were collected through GeneCards,PharmGKB,and OMIM databa-ses.Potential targets of bulleyaconitine A were collected using SwissTargetPrediction and PharmMapper databases.Next,intersection targets were obtained by the Venny 2.1.0 platform.Protein-protein interaction(PPI)network and topology analysis were managed by utilizing the STRING database and Cytoscape 3.8.0.Then,Gene Ontology(GO)and Kyoto Encyclopedia of Genes and Genomes(KEGG)enrichment analyses were conducted in the DAVID database.AutoDock Vina was applied to predict the molecular docking and binding ability of bulleyaconitine A with key targets.Finally,a receptor activator of nuclear factor-κB(RANKL)-induced osteo-clast differentiation model was established in vitro.Quantitative real-time polymerase chain reaction(qRT-PCR)was used to detect the mRNA expression levels of related targets,and immunofluorescence and Western blot were adopted to detect the protein expression level of key targets.It displayed that there was a total of 29 drug-disease targets,and Src was the core target of bulleyaconitine A in an-ti-RA bone destruction.Furthermore,KEGG enrichment analysis revealed that bulleyaconitine A may exert an anti-RA bone destruction effect by regulating the Src/PI3K/Akt signaling pathway.The molecular docking results showed that bulleyaconitine A had better bin-ding ability with Src,phosphatidylinositol-4,5-diphosphate 3-kinase(PIK3CA),and Akt1.The result of the experiment indicated that bulleyaconitine A not only dose-dependently inhibited the mRNA expression levels of osteoclast differentiation-related genes cathepsin K(CTSK)and matrix metalloproteinase-9(MMP-9)(P<0.01),but also significantly reduced the expression of p-c-Src,PI3K,as well as p-Akt in vitro osteoclasts(P<0.01).In summary,bulleyaconitine A may inhibit RA bone destruction by regulating the Src/PI3K/Akt signaling pathway.This study provides experimental support for the treatment of RA bone destruction with bulleyaconitine A and lays a foundation for the clinical application of bulleyaconitine A.
NETL
NSTL
万方数据
